According to the National Comprehensive Cancer Network (NCCN) Guidelines for nonsmall cell lung cancer [15], NSCLC patients in advanced stages showing the EGFR mutations are treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as molecular target therapy [16]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.